UCB (OTCMKTS:UCBJY) Stock Rating Upgraded by The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of UCB (OTCMKTS:UCBJY) to a strong-buy rating in a research report report published on Wednesday morning,Zacks.com reports.

UCB Stock Performance

UCBJY opened at $101.30 on Wednesday. UCB has a twelve month low of $71.16 and a twelve month high of $106.60. The company has a 50-day moving average price of $93.90 and a 200 day moving average price of $93.17. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.99 and a current ratio of 1.36.

UCB Increases Dividend

The company also recently announced a dividend, which was paid on Wednesday, May 14th. Shareholders of record on Tuesday, April 29th were issued a dividend of $0.4838 per share. The ex-dividend date of this dividend was Monday, April 28th. This represents a dividend yield of 0.62%. This is a boost from UCB’s previous dividend of $0.46.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.